biote Corp Acquires Asteria Health

BioMarin Acquires Alesta Therapeutics

August 18, 2026

Biotechnology

BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, plus up to $215 million in development and regulatory milestone payments, to obtain its lead clinical-stage asset, ALE1. The acquisition closed on September 1, 2026; Alesta had spun out its non-ALE1 assets before closing, and became a wholly owned BioMarin subsidiary.

BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics

January 26, 2026

Healthcare Services

BioCryst Pharmaceuticals, Inc. completed its acquisition of Astria Therapeutics, Inc. to strengthen its leadership in hereditary angioedema (HAE) and support long-term growth. The deal adds navenibart, a late-stage long-acting plasma kallikrein inhibitor (Phase 3), and also brings Astria’s early-stage atopic dermatitis program STAR0310 (for strategic alternatives).

Pharmaron Acquires 82.54% of Biortus Biosciences

October 28, 2025

Healthcare Services

Pharmaron Beijing Co., Limited has entered into a definitive Share Purchase Agreement to acquire 82.54% of Biortus Biosciences Co., Ltd. and its affiliates. The transaction is expected to close after satisfaction of customary closing conditions and is intended to strengthen Pharmaron’s structure-based drug discovery and protein science capabilities.

Bristol Myers Squibb to Acquire Orbital Therapeutics in $1.5 Billion Deal

October 11, 2025

Biotechnology

Bristol Myers Squibb (BMS) has entered into an agreement to acquire Orbital Therapeutics, a privately held biotechnology company developing RNA medicines. The $1.5 billion cash deal will give BMS Orbital’s lead candidate OTX-201 and its proprietary RNA platform, supporting BMS’s efforts to advance in vivo CAR T and immunotherapy approaches.

Miura Partners Acquires HTBA (HealthTech BioActives)

November 5, 2024

Biotechnology

Miura Partners has signed an agreement to acquire HTBA (HealthTech BioActives), a Barcelona-headquartered producer of flavonoids and active vitamin B12 used across pharmaceutical, nutraceutical, food & beverage and animal nutrition markets. Miura will pursue organic and inorganic initiatives to consolidate HTBA as a leading platform for natural ingredients; the deal is the third investment from Miura Fund IV and is pending approval from the Spanish regulator.

Haymaker Acquisition Corp. III Merges with Biote

June 3, 2022

Healthcare Services

Haymaker Acquisition Corp. III, a publicly traded SPAC, completed its merger with consumer-directed hormone optimization company Biote (transaction announced Dec 13, 2021; closed May 27, 2022). Biote operates a platform that trains and certifies practitioners and provides practice management software, marketing support and branded nutraceutical products, and had grown a network of roughly 4,700 Biote-certified practitioners in the U.S.